Leveraging HealthFacts RI for Value: Analysis and Recommendations

STAKEHOLDER MEETING PROVIDENCE, RHODE ISLAND MAY 14, 2019



Acknowledgement

The Peterson Center on Healthcare is providing support for this project through June 30, 2019.



The Peterson Center on Healthcare was established by the Peter G. Peterson Foundation to transform US healthcare into a highperformance system by finding innovative solutions that improve quality and lower costs and accelerating their adoption on a national scale.

Welcome

STATE OF RHODE ISLAND

SUPPORT PROVIDED BY THE PETERSON CENTER ON HEALTHCARE


Meeting Agenda

- 1. Overview of the Rhode Island Health Care Cost Trends Project
- 2. Analysis of HealthFacts RI Claim Data
- 3. Washington Health Alliance Experience with Claims Data Analysis and Reporting
- 4. Proposed APCD Data Use Strategy
- 5. Next Steps and Wrap-up

Cost Trends Project Overview

Vision

To provide Rhode Island citizens with high-quality, affordable health care through greater transparency of health care performance and increased accountability by key stakeholders



Health Care Cost Trends Project: Overview

Goals:

- To reduce growth in health care costs by developing a cost growth target and providing transparent health care performance data to influence purchasing decisions and care delivery reforms
- 2. To develop a deeper understanding of the state's health care cost drivers and cost variation
- 3. To create a sustainability plan to support ongoing analyses

A Steering Committee of payers, providers, and other business and community representatives is advising the State on this work.

Cost Trends Steering Committee

Member	Organization				
Tim Babineau, MD	Lifespan				
Al Charbonneau	Rhode Island Business Group on Health				
Tom Croswell	Tufts Health Plan				
Adriana Dawson	Bank Newport				
Jim Fanale, MD	Care New England				
Stephen Farrell	UnitedHealthcare of New England				
Marie Ganim, PhD (Co-Chair)	Office of the Health Insurance Commissioner				
Peter Hollman, MD	Rhode Island Medical Society				
Kim Keck (Co-Chair)	Blue Cross Blue Shield of Rhode Island				
Al Kurose, MD (Co-Chair)	Coastal Medical				
Peter Marino	Neighborhood Health Plan of Rhode Island				
Betty Rambur, PhD, RN, FAAN	University of Rhode Island School of Nursing				
Sam Salganik, Esq.	Rhode Island Parent Information Network				
John Simmons	Rhode Island Public Expenditure Council				
Neil Steinberg	Rhode Island Foundation				
Teresa Paiva Weed, Esq.	Hospital Association of Rhode Island				
Larry Wilson	The Wilson Organization, LLC				

Health Care Cost Trends Project: Three Work Streams

The methodology for a health care <u>cost growth target</u> was to be developed for operationalization in 2019. *This work was completed in December 2018.*



Brown University was to conduct a <u>data analysis</u> to measure health care system cost performance and identify cost drivers. *We will share some of the findings today.*



A <u>data use strategy</u> will be developed to leverage the RI APCD on an ongoing basis in identifying cost drivers and sources of cost growth variation to improve health care system performance. *You will review the draft strategy today.*

Cost Growth Target

Established by Steering Committee member compact in December, and supported by Governor Raimondo's Executive Order in February.

Sets a state per capita cost growth target of 3.2% annually for 2019-2022.

Data will be calculated and reported from Medicare, Medicaid and all major insurers to assess performance at the state, insurance market, insurer and large provider levels.

Performance for 2019 to be reported in the fall of 2020.

Cost Growth Target



Compact Signing - December 19, 2018

Executive Order Signing - February 6, 2019

All-Payer Claims Database (APCD) Analyses

BACKGROUND, COST TRENDS, AND OTHER ANALYSES

STATE OF RHODE ISLAND

NOT FOR CITATION

Agenda: APCD Data Analysis

- 1. Purpose of analyses
- 2. APCD basics
- 3. Missing data
- 4. Cost categories
- 5. Rhode Island health care costs (in national context)
- 6. Deconstructing costs and cost trends
- 7. Low-value care
- 8. High opportunity care episode: knee replacement
- 9. Volume vs. price
- 10. Provider groups in 2017
- **11**. Conclusions

1. Test Health Facts RI (the APCD) as a data source for total cost trend analyses

1. Test Health Facts RI (the APCD) as a data source for total cost trend analyses: current data not sufficiently complete for this purpose.

- 1. Test Health Facts RI (the APCD) as a data source for total cost trend analyses: current data not sufficiently complete for this purpose
- 2. Test the APCD as a data source for analyses of drivers of costs, and drivers of cost trends

- 1. Test Health Facts RI (the APCD) as a data source for total cost trend analyses: current data not sufficiently complete for this purpose.
- 2. Test the APCD as a data source for analyses of drivers of costs, and drivers of cost trends: the APCD is a rich source of data for such analyses

- 1. Test Health Facts RI (the APCD) as a data source for total cost trend analyses: current data not sufficiently complete for this purpose.
- 2. Test the APCD as a data source for analyses of drivers of costs, and drivers of cost trends: the APCD is a rich source of data for such analyses
- 3. Test the APCD as a data source for related analyses that could support cost growth reductions and eventually quality improvement

- 1. Test Health Facts RI (the APCD) as a data source for total cost trend analyses: current data not sufficiently complete for this purpose.
- 2. Test the APCD as a data source for analyses of drivers of costs, and drivers of cost trends: the APCD is a rich source of data for such analyses
- 3. Test the APCD as a data source for related analyses that could support cost growth reductions and eventually quality improvement: the APCD is a rich source of data for such analyses

2. APCD Basics

STATE OF RHODE ISLAND

SUPPORT PROVIDED BY THE PETERSON CENTER ON HEALTHCARE

Payer Classifications


- Commercial (Fully Insured and Self-Insured)
- Medicare Fee-for-Service (FFS)
- Medicare Advantage (including Medicare Advantage + Medicaid)
- Dual Eligibles (those with Medicare + Medicaid)
- Medicaid Managed Care
- Medicaid FFS (note, very few in RI currently)

APCD Population (2014-2017)

Total unique persons	1,184,991
At least 1m enrolled	1,144,224 (96.6%)
Exclude minor plans	1,079,781 (91.1%)
At least 1m RI resident	1,039,435 (87.7%)
Total enrolled months 12+	932,642 (78.7)
Continuously enrolled 12m	923,246 (77.9)


Total RI Population in 2017: 1.056M

APCD Basics: Total Enrolled





Supreme Court decision, Gobeille v Liberty Mutual (March 1, 2016): held (6-2) that the Employee Retirement Income Security Act (ERISA) invalidates state all-payer claims database (APCD) reporting requirements for self-funded employee health plans

Total Enrolled by Payer Type



STATE OF RHODE ISLAND





STATE OF RHODE ISLAND

3. Missing Data

APCD: Structurally Missing Data

- Non-claims payments
 - Incentive payments (e.g., PCMH, ACO-related)
 - Carve outs (e.g., behavioral health, pharmacy)
- Self-insured data (per Gobeille decision)
- Our analyses have identified some other missing data: this is in the process of being corrected

Non-Claims Payments

Non-Claims Payments

Payer	% Non-Claims	Pattern 2014-2017
BCBS	1.5% - 3.4%	Slow increase
United	2-3%	Stable
NHP	?	?
Tufts	3-5%	Slow increase

Missing Data: Self-Insured Population

2017 Data for Self-Insured Patients by Payer

	BCBS		United		Tufts	
Comparators	In	Out	In	Out	In	Out
Percent	88	12	55	45	14	86
Risk Score	1.50	1.24	n/a	n/a	1.51	1.62
TMC, PMPM	\$376	\$343	\$453	\$346	\$464	\$574
% Difference PMPM		-9.6%		-30.9 %		+19.2%

TMC: total medical cost **PMPM**: per member per month

Conclusions: Missing Data

- To date, the fraction of total costs that are non-claims-based payments is small, but as we have discussed, this percentage is likely to increase over time
- "Included" self-insured patients compared to "non-included" self-insured patients differ substantially, which is clearly a problem if we want to look at valid cost trends
- Until these different types of missing data can be included in the APCD (2-4 years), the APCD should not be used to assess trends in total costs

4. Cost Categories

STATE OF RHODE ISLAND

SUPPORT PROVIDED BY THE PETERSON CENTER ON HEALTHCARE

Health Care Cost Institute (HCCI)

2017 Health Care Cost and Utilization Report

HEALTH CARE

COST INSTITUTE



- Replicated their methodology to the extent possible
- Their methodology is respected and very clearly explained in methods documents
- Allows direct comparisons between their national commercial data and RI commercial data

February 2019

HCCI Cost Sub-Categories

- Inpatient
- Outpatient
- Professional Services
- Prescription Drugs

5. Rhode Island Health Care Costs

RHODE ISLAND HEALTH CARE COSTS IN NATIONAL CONTEXT

RI in National Context

WEB FIRST

By David Lassman, Andrea M. Sisko, Aaron Catlin, Mary Carol Barron, Joseph Benson, Gigi A. Cuckler, Micah Hartman, Anne B. Martin, and Lekha Whittle

DOI: 10.1377/htmaff.2017.0416 HEALTH AFFAIRS 36, NO. 7 (2017): 1318-1327 ©2017 Project HOPE— The People-to-People Health Foundation, Inc.

Health Spending By State 1991–2014: Measuring Per Capita Spending By Payers And Programs

David Lassman (David

Lassman2@cms.hhs.gov) is a statistician in the Office of the Actuary, Centers for Medicare and Medicaid Services (CMS), in Baltimore, Maryland.

Andrea M. Sisko is an economist in the CMS Office of the Actuary.

Aaron Catlin is a deputy director of the National Health Statistics group in the CMS Office of the Actuary.


Mary Carol Barron is an economist in the CMS Office of the Actuary.

Joseph Benson is an

ABSTRACT As the US health sector evolves and changes, it is informative to estimate and analyze health spending trends at the state level. These estimates, which provide information about consumption of health care by residents of a state, serve as a baseline for state and national-level policy discussions. This study examines per capita health spending by state of residence and per enrollee spending for the three largest payers (Medicare, Medicaid, and private health insurance) through 2014. Moreover, it discusses in detail the impacts of the Affordable Care Act implementation and the most recent economic recession and recovery on health spending at the state level. According to this analysis, these factors affected overall annual growth in state health spending and the payers and programs that paid for that care. They did not, however, substantially change state rankings based on per capita spending levels over the period.

EXHIBIT 2

Per capita personal health care spending by state of residence, calendar year 2014



New England is the highest cost region in the US

sources Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group; and Census Bureau.

EXHIBIT 1

Per capita personal health care spending and average annual changes in selected time periods, by region and state of residence, 2004–14

	State	Personal health care spending			Average annual change		
Region		2009	2013	2014	2004-9	2010-13	2014
United States		\$ 6,892	\$ 7,703	\$ 8,045	5.2%	2.8%	4.4%
New England	Connecticut Maine Massachusetts New Hampshire Rhode Island	8,740 8,359 9,417 8,134 8,393	9,517 9,133 10,273 9,369 9,160	9,859 9,531 10,559 9,589 9,551	5.8 5.4 6.1 7.6 5.7	2.2 2.2 2.2 3.6 2.2	3.6 4.4 2.8 2.4 4.3
	Vermont	8,111	9,919	10,190	5.9	5.2	2.7

Compared with other NE states, RI is consistently one of the lowest spending states, but *compared with the rest of the country*, RI is clearly one of the higher spending states.

6. Deconstructing Costs and Cost Trends


NOT FOR CITATION. THE PURPOSE OF THIS EXERCISE IS TO DEMONSTRATE HOW THESE DATA CAN BE PRODUCTIVELY USED.

Cost Trends vs. Cost Drivers

 While imperfect at the moment for measuring total costs and cost trends, APCD data are critical to the understanding of *drivers of cost* and *drivers of cost trends*


- Drivers of costs and drivers of cost trends cannot be understood at the state level without multi-payer data
- What follows are demonstrations of the value of APCD data in understanding these drivers for commercial insurance

Annual Cost Trends, All Payers, PMPY




Note that there are 95,301 fewer patients in 2016 than 2015. We do not include the 2017 data because the Medicare FFS 4th quarter data has just arrived.

Annual Cost Trends, Commercial, PMPY



We know that data problems caused the 2015 cost data to be too low (being fixed). Again note that there are over 100K fewer patients in 2015 than 2016.

Annual Cost Trends, Commercial, PMPY



Notwithstanding these data issues, what can these data tell us about drivers of cost and cost trends?


Cost Category Trends, Commercial



We know these are artificially low (missing data).


Cost Category Trends, Commercial

Distribution of Yearly Per Person Cost Over Time in Major Categories-Commercial




Drugs show 36% increase in 3 years. Clearly drugs are drivers of both *total costs* and *cost trends* for commercially insured.

What are the Drivers of Drug Costs?



Drugs can of course be further broken down into different classes.



Generic name	Brand name	Indication	
Anti-infective			
ledipasvir-sofosbuvir	Harvoni	Hepatitis C	
efavirenz/emtricitabine/tenofovir	Atripla	HIV	
emtricitabine-tenofovir	Truvada	HIV/HIV prevention	
CNS agents			
amphetamine-dextroamphetamine	Adderall	ADHD	
methylphenidate lisdexamfetamine	Vyvanse	ADHD	
lisdexamfetamine	Vyvance	ADHD	
Immunologic agents			
glatiramer	Copaxone	MS	
dimethyl fumarate	Tecfidera	MS	
fingolimod	Gilenya	MS	
Metabolic agents			
insulin glargine	Many	Long acting insulin	
rosuvastatin	Crestor	Cholesterol lowering	
insulin lispro	Humalog	Short acting insulin	
Miscellaneous			
adalimumab	Humira	Crohn's Dz, psoriasis	
etanercept	Embrel	RA, psoriasis	
inFLIXimab	Remicaid	RA, psoriasis	

For each of these 5 drug classes, the three top individual drugs and their indications are listed.

Conclusions (Commercial)

Main point here is not what the total cost trends are; we know that we are missing data needed to accurately describe these trends. Rather, these data can show a lot about *drivers of cost* and *drivers of cost trends*

- Total PMPY inpatient, outpatient, and professional costs all increased over the 4-year period; but drug costs increased dramatically
- Note that 25-30% of drug costs are bundled into inpatient and professional costs, so we are not even seeing the full impact of drug costs here
- We have completed other similar analyses for other payers

7. Low-Value Care

STATE OF RHODE ISLAND

SUPPORT PROVIDED BY THE PETERSON CENTER ON HEALTHCARE

Definition of Low-Value Care

 For each of the 16 low-value care measures, we identified "qualifying visits" at which patients were eligible to receive low-value services based on qualifying diagnoses and exclusions.

- Denominator = Total qualifying visits
- Numerator = Total visits that included a low value service

Definition of Low-Value Care

Example:

Numerator: Visits with a diagnosis of headache but no current diagnosis or oneyear medical history of epilepsy that included an electroencephalogram service.

Denominator: Total visits with a diagnosis of headache but no current diagnosis or 1-year medical history of epilepsy.


Common Types of Low-Value Care

We have data on 16 different types of Low-Value Care. Examples include:


- 1. Arthroscopic surgery for knee osteoarthritis
- 2. Head imaging for uncomplicated headache
- 3. Head imaging for syncope
- 4. EEG for headaches
- 5. Abdominal CT combination studies (abdomen/pelvis)

Overall Trends (all Payers)


Low Value Care Trend




Levels of low-value care clearly vary from one measure to the next.



Head Imaging for Uncomplicated Headache




Head Imaging for Syncope




Similar 2-2.5 fold variation, but with a different payer with the highest rate.

Medicaid=Medicaid FFS MCO=Medicaid MC



Abdomen CT Combined Studies



Conclusions: Low-Value Care

- Low-value care can be identified in RI APCD data.
- Rates and variations in rates are substantial.
- Tremendous opportunities to reduce unnecessary costs.


8. High Opportunity Care Episodes


KNEE REPLACEMENT

Total Knee Replacement (TKR) "Episodes"


- In this case the "episode" includes all of the costs associated with the hospitalization only
- "Bundles" for orthopedic procedures can also include pre and post-operative care outside of the hospitalization for the surgery; we defined "episode" more narrowly for this analysis

Trends in # of persons with TKR, All Payers






Trends in #s of persons with TKR, by payer. Note that there are no prominent upward trends.



Trends in total paid amounts for TKR per patient, by payer. Trends flat to downward, but note differences between payers.


Again we see drop in last quarter of 2015 (BCBS missing data).

TKR Episode Costs by Payer



Clearly there is variation within payer groups.

Total episode cost, commercial payers, by hospital (labeled A, B, C, D, E)



Clearly there is cost variation at the hospital level for TKRs paid for by commercial payers.


TKR: Volume and Price Trends

- Volume does not appear to be increasing with time.
- This is a vivid demonstration of how prices differ by payer.
- In addition, this demonstrates how prices differ by hospital.
- We tried to understand whether TKR could be traditional TKR and the more modern resurfacing procedures that are advertised in the state. This distinction is probably not possible using CPT codes.
- Note that these data have not been risk-adjusted.

9. Volume vs. Price


DRUG COSTS AS AN EXAMPLE

Percent change in total drug costs, by payer, by year, compared to 2014



Percent change in total drug costs, by payer, by year, compared to 2014

Decomposed into utilization (dotted line) and price



Conclusions


- Decomposing costs into utilization and price per unit is critical.
- Increases in both utilization and price drive commercial drug costs.
- Very different patterns are seen in Medicare Advantage and Medicare FFS as compared with commercial and Medicaid Managed Care.
- Reminder that baseline costs may be higher than optimal.

10. Provider Groups in 2017

Background

- Ability to examine and compare the all-payer performance of provider groups is a critical innovation.
- Because patients in the APCD are de-identified, we have to use patient utilization data to link or attribute patients to providers.
- Providers can then be linked to provider groups and ACOs/AEs.
- Attribution algorithms are complex and computationally intensive.
- Data linking providers to payers, groups, and ACOs/AEs is imperfect.
- All such comparisons require risk adjustment.

Attributing Patients to Providers and Groups



OHIC datasets used to link providers to practice groups and ACOs

Attributing patients to providers

- Look back 27 months
- Identify physicians who provided primary care services
- Attribute the patient to the provider with the plurality of services provided

Initial Attribution Results, 2017

- 1433 unique PCPs in OHIC datasets
- 689,409 unique patients
 - 12.4% (85,527) unattributed
 - 87.6% (603,883) attributed to a PCP
 - 76.3% of all patients (525,909) attributed to a PCP in the OHIC dataset
- Reasons for non-attribution
 - No PCP visits (presumably health people who did not get routine primary care)
 - Attribution to a PCP not in our dataset, perhaps a specialist acting as a PCP

Initial Attribution Results, 2017

- ACOs/AEs in dataset
 - Blackstone Valley Community Health Center (BVCHC)
 - Coastal Medical
 - Integrated Health Partners (IHP)
 - Integra
 - Lifespan
 - Providence Community Health Centers (PCHC)
 - Prospect/Chartercare
- With exception of BVCHC, the number of attributed patients ranges from 25K to 140K – large enough numbers for valid comparisons

Conclusions and Next Steps

- Attribution process performing about as expected.
- Checking and validation of initial attribution results underway.
- Longer-term goal: valid comparisons between ACOs
 - Note that many such comparisons require careful attention to risk adjustment.
 - We are working with "Clinical Risk Groups" or CRGs, a 3M risk-adjustment product that has been used by VT in their APCD work.

11. APCD Data Analysis Conclusions

Conclusions

1. Is Health Facts RI (the APCD) IN ITS CURRENT FORM a viable data source for:

- Total cost trend analysis? NO
- Drivers of cost (levels of cost, price and use)? YES
- Drivers of cost trends? YES
- Related analyses that could support cost growth reductions and/or quality improvement? YES
- Comparisons with benchmarks? YES

Conclusions

2. Next Steps

- Attribute patients to PCPs
- Examine trends by provider groups (ACOs)
- Integrate risk adjustment where appropriate
- Examine other examples of "high opportunity" episodes (e.g., maternity care, hip replacement, care of diabetics, etc.)
- Incorporate benchmarks
- Further analyze utilization and price
- Examine of out-of-pocket costs

WA's Experience with Claims Data Analysis and Reporting

THE WASHINGTON HEALTH ALLIANCE STORY

Proposed APCD Data Use Strategy

DRAFT STRATEGY FOR DISCUSSION

Data Use Strategy Introduction

•There were 16 operational state APCDs as of January 2019, with relatively few being effectively leveraged to propel improved health care affordability and quality.

The development of a strategy to make better use of HealthFacts RI, Rhode Island's All-Payer Claims database, lies at the heart of the Cost Trends Project. November 2018 Conference: Leveraging Multi-Payer Claims Databases for Value

Work on the data use strategy began with a 11-14-18 invitational one-day conference. The conference was organized with two objectives:

Objective #1: Learn from individuals from other states whose organizations were currently using multi-payer claims databases

Objective #2: Identify strategies to leverage RI's APCD to enhance the value of health care in Rhode Island

Data Use Categories and Speakers

	Data Use Category		State/Organization Invitee
1.	Support ongoing regulatory activity and analysis of potential policy initiatives	•	Tyler Brannen, New Hampshire Insurance Department Stacey Schubert, Oregon Health Authority
2.	Promote transparency for consumers and policymakers with cost and quality reporting and tools	•	Nancy Giunto, Washington Health Alliance David Auerbach, Massachusetts Health Policy Commission
3.	Support specific regional or provider-level delivery system activity	•	Mary Kate Mohlman, Vermont Blueprint for Health

 Actively and continuously engage stakeholders. Continuous provider and payer engagement are critical to building buy-in and trust, and the State can play the important role of convener. A "co-development" process with providers and payers engaged on the front end allows for collective decision-making about how to best enhance and leverage the APCD.

2. Responsibly test and then release data. Data that have been adequately and thoroughly tested, validated, reviewed and analyzed should provide a measure of confidence of readiness for release. Content experts indicated that data integrity does not mean 100% data certainty. National experts and those speaking from experience using multi-payer claims databases suggested a dry run with providers and payers to provide an opportunity to address inconsistencies or errors prior to public release.

3. Develop a sustainable funding model. Currently, HealthFacts RI is sustained through Medicaid funding with the state portion of the funding coming from data release fees. Fees are appropriate to assure data requests are valid and from reliable sources, but should not be cost-prohibitive for researchers, as they appear to be. In addition, the State should examine the resources allocated to administering and maintaining the APCD to ensure there are sufficient funds and staff dedicated achieving the goals of the APCD.

4. Make unwarranted variation transparent. Exposing variation in utilization, cost, price and quality is an essential use of an APCD dataset. This may be reported at the provider, payer, service and / or geographic levels. Examining variability and benchmarking performance of providers can reveal areas of opportunities for which the State or providers may wish to focus attention and resources.

5. Identify cost drivers. Using HealthFacts RI to better understand the primary health care cost drivers in the state is also an essential use of the APCD dataset. The analysis would reveal areas that are contributing in an outsized way to health care spending and focus attention and resources on strategies and interventions to slow the growth. Such analysis would support provider and payer efforts to meet the state's new cost growth target.

6. Consider the development of a community analytics resource. There are many providers and payers in Rhode Island that have invested in and developed sophisticated data analytics capabilities to manage health care costs and utilization. It is important to consider how a data use strategy for HealthFacts RI can focus resources to support providers with less advanced data capabilities and not duplicate efforts.

Post-Conference Activity

•Follow-up conversations with the November conference presenters to further explore their activities and learnings

- Focus groups with physicians, non-physician clinicians and other provider representatives
- •Multiple Steering Committee discussions of priorities for use of the APCD
- •Dissemination of draft strategy document for Steering Committee comment (twice) and for public comment, and then revisions.

APCD Data Use Strategy Proposal

The Steering Committee considered two types of analyses that can be performed with HealthFacts RI data:

- 1. routinely produced, commonly structured analyses to be published on a regular schedule, and
- 2. ad hoc analyses focusing on discrete topics of interest to the State and to Rhode Island stakeholders.

This recommended APCD data use strategy focuses upon the former - routinely produced, commonly structured analyses to be published on a regular schedule.

APCD Data Use Strategy Proposal

The Steering Committee agreed upon the following when shaping its recommendations:

- 1. Prioritize reports first for provider use, and second for the general public.
- 2. Don't focus on payers and consumers as priority audiences. Payers already possess claim data, and research repeatedly shows consumers don't use health care performance data.
- 3. Generate reports that isolate what is driving underlying cost <u>and</u> what is driving cost growth, with the former the highest priority.
- Because there is already significant RI measurement activity related to quality, and some degree of related transparency, focus first on measurement associated with spending.

APCD Data Use Strategy Proposal

The Steering Committee recommends that a data use strategy for HealthFacts RI focus upon <u>five types of analyses</u>.

Each of type of analysis should produce a report that:

- is produced with stratification by insurance coverage (e.g., commercial, Medicaid, Medicare);
- is produced by provider and, when appropriate, by geography;
- when possible, incorporates stratification of children and adults, and
- displays performance change over time.

The State should ensure that only statistically valid performance data are published.


Five Recommended Analyses for Public Reporting - in Priority Order

- 1. cost drivers
 - utilization variation: frequency, intensity and site of care
 - price and cost variation: by service (price) and by episode of care (cost)
- 2. cost growth drivers
- 3. cost drivers (cont'd)
 - low-value services
 - potentially preventable services
- 4. population demographics, including social determinants of health
- 5. quality of care


Report Type #1: Cost Drivers

- •Isolates the impact of service utilization and unit price/cost.
- •Looks at how cost drivers vary within RI (by geography, payer, population, insurer, large provider)
- •Looks at how performance compares to benchmarks external to RI (to the extent available)


Report Type #1: Cost Drivers Vermont Utilization Example



Report Type #1: Cost Drivers Massachusetts Cost Example



Report Type #1: Cost Drivers Rhode Island Cost Example



Report Type #2: Cost Growth Drivers

•Identifies the factors that most contributed to cost growth over time (one year or more)

•Can provide insight into the causes underlying performance relative to the annual Cost Growth Target of 3.2%

Report Type #2: Cost Growth Drivers Washington Health Alliance Example


					41	What is con	-	16 4 1	
	THIS YEAR's	LAST YEAR's			changes in Age/Gender	change in sp changes in Service	changesin Treatment	changesin	
	Spending	Spending	Change	Change	Mix	Frequency	Intensity	Price Level	Total Change
Service	(PMPM)	(PMPM)	(%)	(PMPM)	account for:	account for:	account for:	account for:	in Spending
Pulmonary Edema	\$22.90	\$21.99	4.2%	\$0.92	\$0.08	(\$0.05)	(\$0.01)	\$0.89	\$20,612
COPD	\$18.99	\$17.66	7.5%	\$1.33	\$0.11	\$0.25	\$0.44	\$0.53	\$29,908
Pneumonia	\$27.32	\$25.40	7.5%	\$1.91	\$0.17	\$0.14	\$0.16	\$1.43	\$43,023
Perc CV Procedures	\$26.45	\$25.13	5,3%	\$1.32	\$0.15	\$0.03	\$0.03	\$1.12	\$29,756
Circulatory Disorders	\$18.88	\$18.12	4.2%	\$0.76	\$0.09	\$0.00	\$0.01	\$0.65	\$16,988
Heart Failure	\$22.77	\$22.31	2.0%	\$0, 46	\$0.06	(\$0.00)	(\$0.00)	\$0.40	\$10,246
Cardiac Arrhythmia	\$27.33	\$26.51	3.1%	\$0.82	\$0.09	\$0.01	\$0.05	\$0.66	\$18,445
Spinal Fusion	\$13.70	\$12.88	6,4%	\$0.82	\$0.06	\$0.33	\$0.08	\$0.35	\$18,492
Major Joint Replacement	\$16.08	\$15.11	6.4%	\$0.96	\$0.08	\$0.14	\$0.20	\$0.55	\$21,706
Cellulitis	\$28.26	\$25.72	9,9%	\$2.54	\$0.13	\$1.53	\$0.01	\$0.89	\$57,227
Metabolic disorders	\$19.26	\$17.53	9,9%	\$1.73	\$0.07	(\$0.06)	(\$0.01)	\$1.73	\$39,006
Urinary Tract Infections	\$23.01	\$22.55	2.0%	\$0, 46	\$0.03	\$0.18	\$0.27	(\$0.01)	\$10,355
Septicemia	\$10.93	\$10.60	3.1%	\$0,33	\$0.01	\$0.12	\$0.13	\$0.07	\$7,377
	\$275.87	\$261.51	5.5%	\$14.36	\$1.13	\$2.62	\$1.35	\$9.27	\$323,141
					8%	18%	9%	65%	

Report Type #3: Cost Drivers (Cont'd)


 Focuses on utilization and spending associated with poor quality care due to overuse and underuse

- olow-value services: services that produce little to no benefit to the patient
- <u>potentially preventable services</u>: spending on acute services that could have been avoided if preceded by high quality ambulatory care

Report Type #3: Mass. Low-Value Care Example



Report Type #3: Mass. Potentially Preventable Example



Emergency Department Visits

Report Type #4: Population Demographics

•Involves supplementing the APCD with data from other sources (e.g., race, language, ethnicity, housing status, income, etc.) to facilitate identification of high-risk communities, and more generally enhance an understanding of served communities.

• "Hot spotting" analysis could help providers target particular highrisk communities, and even neighborhoods, within their service area.

Report Type #4: Mass. Pop. Demographics Example


	Risk score	Zip-code income	Area deprivation index	% over 55	% Self- insured	% Female
Atrius	.96	\$83,284	76.7	26%	52%	56.4%
BMC	.89	\$63,319	88.5	20%	52%	54.2%
Lahey	1.05	\$85,677	77.8	31%	43%	51.7%
MACIPA	.94	\$85,615	70.1	28%	47%	53.5%
Partners	1.03	\$86,017	76.6	29%	44%	55.5%
Southcoast	1.09	\$59,721	97.6	30%	50%	51.4%
Steward	1.05	\$70,131	90.1	30%	48%	52.4%
All physician-led	.96	\$81,723	80.2	25.8%	47.8%	55.3%
All other hospital- anchored	1.02	\$74,485	86.6	29.8%	45.7%	52.6%
All AMC-anchored	1.02	\$81,646	80.7	28.3%	44.5%	53.7%

Report Type #5: Quality

•While there are limitations to how quality can be measured using claim data alone, there are valid and valuable measures for which claim data can be useful (e.g., readmission rates).

•Quality reports would focus on aspects of performance for which comparative analyses are not currently available.

Report Type #5: Rhode Island Quality Example



STATE OF RHODE ISLAND

Report Type #5: Washington Health Alliance Quality Example



Powered by:

Figure 18: Ranking Medical Group Performance for Commercially Insured: Medical Groups That Have Results for 15 or More Measures

Medical Group	<	WORSE	n	- AVERAGE -		BETTER	>
Kaiser Permanente Washington			1	7	21		
Virginia Mason Medical Center				10	19		
Pacific Medical Centers			1	10	14		
Swedish Medical Group			1	17	10	1	
The Everett Clinic			2	15	13		
The Polyclinic			2	14	12		
UW Medicine - Valley Medical Group			1	18	9		
UW Neighborhood Clinics			1	18			
Columbia Medical Associates			1	15	8		
Family Care Network			1/64	14	10		
MultiCare Rockwood Clinic**			4	To	9		
University of Washington Medical Center			3	14	8		
Summit View Clinic			3	74	5		
MultiCare Health System**			5	19	A.C.		
Trios Medical Group**			а	13	5		
Family Health Care of Ellensburg				14			
North Olympic Healthcare Network**			0	12	3		
Sound Family Medicine			5	21	2		
Capital Medical Center			2	16	1		
Providence Physicians Group			6	18	4		
Island Hospital			2	11	3		
Peninsula Community Health Services**			2	11	a.		
	30	20	10	0	10	20	3

Discussion

SHOULD THE PROPOSED APCD DATA USE STRATEGY BE MODIFIED, AND IF SO, HOW?

Next Steps and Wrap-up

STATE OF RHODE ISLAND

SUPPORT PROVIDED BY THE PETERSON CENTER ON HEALTHCARE

Next Steps

•Thank you for participating in the meeting today!

•The project team will consider your feedback as it continues to refine its APCD analyses.

•The project team will also incorporate your feedback on the data use strategy into the final RI Cost Trends Project Data Use Strategy, which will be posted on the OHIC website by the end of June: <u>http://www.ohic.ri.gov/ohic-reformandpolicy-costtrends.php</u>.

Thank you!